Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilaris in Muckle-Wells Syndrome
NCT00465985Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2007
- Primary completion
- Oct 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of canakinumab in Muckle-Wells syndrome (MWS), sponsored by Novartis. Started Apr 2007; status: completed.
02
Drugs
canakinumab
03
Conditions
Muckle-Wells syndrome (MWS)
Beyond the preview
Go deeper on NCT00465985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00465985.